# Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy

> **NCT01138202** · PHASE2 · COMPLETED · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections
- Tuberculosis

## Interventions

- **DRUG:** LPV/r

## Key facts

- **NCT ID:** NCT01138202
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138202, "Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01138202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*